PMR

renal.genes_.jpg

Biologics Prevent AA amyloidosis progression to ESRD

MedPage Today

One of the most serious complications of rheumat0logic and autoimmune diseases can be prevented with biologic drugs, a single-center chart review suggested, and some such products may be more effective than others.

Among 83 patients receiving biologic agents for their underlying

Read Article
From LG cohort of myeloid neoplasms (861 MDS, 640 AML, 112 MDS/MPN, 89 MPN) autoimmune Rheum Dz (AIRD) found in 7.7% (lit suggests 8-30%), less in AML (4.7% vs 9.5% others). Common: RA (42%), CTD(18%), PMR (14%), vasculitis (12%), AxSpA (7%). https://t.co/ZXxOrZBunZ https://t.co/m5nIgrhohw

Links:

Dr. John Cush @RheumNow( View Tweet )
JAMA Patient Education Handout on Polymyalgia Rheumatica (PMR) https://t.co/J1rpcRltM3 https://t.co/gEUcbE1FuP

Links:

Dr. John Cush @RheumNow( View Tweet )
PMR - a Risk Factor for Recalcitrant Giant Cell Arteritis? Despite the clinical similarities and treatment differences between giant cell arteritis (GCA polymyalgia rheumatica (PMR), confusion exists regarding the impact of overlapping disorders. https://t.co/Slnq68YQgh https://t.co/nCYswGmlCk

Links:

Dr. John Cush @RheumNow( View Tweet )
PMR spotlight

PMR - a Risk Factor for Recalcitrant Giant Cell Arteritis?

Jack Cush, MD

Despite the clinical similarities and treatment differences between  giant cell arteritis (GCA polymyalgia rheumatica (PMR), confusion exists regarding the impact of overlapping disorders. A large cohort study shows that GCA patients with PMR symptoms are

Read Article
PMR has distinct patterns on MRI shoulder, possibly helping Dx. #EULAR2024 OP0248 @drdavidliew also @bmj_rmdopen https://t.co/0J3xUmb9yt where they say: "Similar to our prior findings... the target of inflammation in PMR is the outer covering of a tendon, the peritendineum" https://t.co/AzWkg3z2vR

Links:

Dr. John Cush @RheumNow( View Tweet )
GCA,woman

Choices in GCA

David Liew, FRACP

There are a number of diseases where new biologic and targeted synthetic therapeutic options are coming online, and the temptation will be to consider them all equally. GCA is one of those diseases.

Read Article
PMR has distinct patterns on MRI shoulder, possibly helping diagnosis. #EULAR2024 OP0248 @RheumNow also @bmj_rmdopen https://t.co/pS5kO5OQRW where they say: "Similar to our prior findings... the target of inflammation in PMR is the outer covering of a tendon, the peritendineum" https://t.co/5pu1Xiku3h

Links:

David Liew @drdavidliew( View Tweet )
PMR patients get too much steroid. Data across 27 million people in England, n=39,438 with PMR. The blue are getting more pred than guidelines. Like everything in rheum: we need to be giving less pred, not more. Lumping PMR in with GCA won’t help. #EULAR2024 POS0411 @RheumNow https://t.co/bsi3lrAafm

Links:

David Liew @drdavidliew( View Tweet )
Enjoyed the #PolymyalgiaRheumatica session at #EULAR2024? Make sure to download our first atlas imaging article, where @drceowen, @drdavidliew et al. characterise PMR using whole-body PET/CT 👀 ➡️ https://t.co/tbu0DgAFIS https://t.co/W06YbYyjRx

Links:

Rheumatology & Rheumatology Advances in Practice @RheumJnl( View Tweet )
#EULAR2024 POS1420 A cohort study with 1/3 each with GCA, PMR and GCA+PMR found that at 6mth, 16% of patients had new diabetes/diabetes worsened. Worse in GCA+PMR group with the greatest GC accumulation. Call for better GC-sparing strategy @RheumNow https://t.co/ex7u83bVfj

Links:

Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
Predicting who will develop ▶️#GCA In #Swedish study with #PMR ⬆️ in HIGH ESR/CRP ⬆️female ⬇️ if hip pain/stiffness Not all sig 1 mo after #prednisone started Only 9% with #polymyalgia #rheumatica developed #GCA ? ⬇️GCA % in PMR over time #POS0411 @eular_org @RheumNow https://t.co/UMhxlYd0Pv

Links:

Janet Pope @Janetbirdope( View Tweet )
Leflunomide for #PMR? ✅ #Leflunomide FAR more effective than #MTX in #polymyalgia #rheumatica V fast withdrawal of #prednisone #LEF ~4 to 5 months #MTX 30 mos! ⬇️flares w LEF 😮 #EULAR2024 @RheumNow @eular_org @SebaUltraTrail https://t.co/2hk0yMH6gY

Links:

Janet Pope @Janetbirdope( View Tweet )
podcast logo

"Don't You Know Who I am?" (5.17.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past 2 weeks. This week's question: can we prevent gout, ILD or psoriasis?

Read Article
National French study finds post COVID Vaccine the IR of PMR (179 cases; RR 7.1/mill) & GCA (54 cases; RR 2.1 /million) were reported 7-10d post vax. These #s are below population incidence rates (1-20/mill for GCA) https://t.co/XvaoWhqs2g https://t.co/BFDy2WKcLx

Links:

Dr. John Cush @RheumNow( View Tweet )
337 PMR pts studied by FDG PET, followed 6 mos - 9% (31) had subclinical vasculitis (GCA) - 21 had isolated LG vessel - 3 isolated cranial vasculitis - 7 both cranial & LG vessel vasculitis. Steroid use higher w/ subclinical vasculitis, but not relapse https://t.co/uwXf4ucVnQ https://t.co/AOacTnQZaS

Links:

Dr. John Cush @RheumNow( View Tweet )
RheumNow Podcast square

1/600 Falls May Die (4.5.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news and Journal reports from this past week on RheumNow.com -  including problems w/ falls, pain and treatment of Dupuytren’s contractures.

Read Article
337 PMR pts studied by FDG PET, followed 6 mos - 9% (31) had subclinical vasculitis (GCA) - 21 had isolated LG vessel - 3 isolated cranial vasculitis - 7 both cranial & LG vessel vasculitis. Steroid use higher w/ subclinical vasculitis, but not relapse https://t.co/QyRFwY45eU https://t.co/rg1WSBeMFl

Links:

Dr. John Cush @RheumNow( View Tweet )
Should all patients with #polymyalgia rheumatics be screened for #giantcellarteriitis with vascular #ultrasound? A recent viewpoint summarizes the evidence: 📊prevalence of subclinical GCA may be as high as 25% https://t.co/UL6gWRdE5R https://t.co/EAlRyNNWYt

Links:

Annals of the Rheumatic Diseases @ARD_BMJ( View Tweet )
2023

2023 Rheumatology Year in Review

Jack Cush, MD

Dr. Jack Cush reviews highlights, advances and hot topics in rheumatology from 2023 and the RheumNow website.  



2023 was a year of growth and new horizons while returning to operational and practice standards (in care and education) established before the pandemic.  

Read Article
ICYMI: When PMR Strikes Young, It Hits Hard https://t.co/rUuPnbcgCY https://t.co/AMpqGCJhIa

Links:

Dr. John Cush @RheumNow( View Tweet )
2023, Year, Wordle

2023 Rheumatology Year in Review

Jack Cush, MD

Here is my top 10 list (in no particular order) of 2023 advances, game-changers, and developments that changed, or will soon change, rheumatologic practices.

Read Article
Full Read review of #PMR in Lancet: - Start @ 12·5–25mg prednisone qd - Remission in most but, relapses in 40–60% - Onset sudden; AM stiffness predominates; Shoulders>Pelvic ~50% have distal MSK Sxs - US: look for B/L sub-acromial/deltoid bursitis https://t.co/NwrbdMMdLU https://t.co/eRls0fLMJs

Links:

Dr. John Cush @RheumNow( View Tweet )
Best of 2023: PMR: glad or bad tidings? “Life was turned upside down overnight” – PMR patient. https://t.co/l7jZei5Kfm https://t.co/Ct3qlHd34P

Links:

Dr. John Cush @RheumNow( View Tweet )
When should we be starting therapy in GCA and PMR? The problem with having therapies that work is that you then have to figure out what to do with them. You cannot hide behind the ambiguity of therapeutic inadequacy. https://t.co/oRWTeH5Q9h https://t.co/BbswdffoKM

Links:

Dr. John Cush @RheumNow( View Tweet )

Recent Blogs

Best of 2023: PMR: glad or bad tidings?

Sarah Mackie, MRCP, PhD
Smile feedback opinion yes no good back opinion
Please don’t tell your patient that PMR “typically” lasts two years. According to real-world data from the UK, one in four patients with PMR is prescribed steroids by their primary care physician for over four years. But nobody tells them this at the start, and that causes big problems later on. Read Post

Advancing PMR

Eric L. Matteson, MD, MPH
Dr. Eric Matteson
Even though polymyalgia rheumatica is not perceived by many physicians as a severe diagnosis, its diagnosis and management actually propose significant challenges. I'd like to talk about those challenges, and what directions our path forward can include to advance our understanding and improve the treatment of patients who have PMR. Read Post

Featured Video

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.